- ►diabetesjournals.org J Plank, A Wutte, G Brunner, A Siebenhofer, … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—With respect to blood glucose excursions from time 0 to 6 h (Exc
glu(0–6 h) ) and from time 0 to 4 h (Exc glu(0–4 h) ), the pharmacodynamic
effect of insulin aspart and insulin lispro can be declared equivalent. ... Cited by 76 - Related articles - BL Direct - All 6 versions
- ►clinchem.org WE Owen, WL Roberts - Clinical Chemistry, 2004 - Am Assoc Clin Chem Several new insulin analogs that are prepared with recombinant DNA technology
are available for clinical use [for a recent review, see Ref. (1)]. These agents
have altered pharmacokinetics compared with regular human insulin. Insulin ... Cited by 18 - Related articles - BL Direct - All 4 versions
M Thevis, A Thomas, W Schanzer - Mass Spectrometry Reviews, 2008 - assets0.pubget.com Insulins' anabolic and anti-catabolic properties have sup- posedly led to its
misuse in sport. Hence, doping control assays were developed to allow the
unequivocal identification of synthetic insulin analogs and metabolic ... Cited by 13 - Related articles - View as HTML - BL Direct - All 3 versions
- ►diabetesjournals.org UB Johansson, S Amsberg, L Hannerz, R … - Diabetes care, 2005 - Am Diabetes Assoc Lipohypertrophy is a common side effect of subcutaneous insulin therapy,
occurring in up to 50% of patients with type 1 diabetes (1–3). It is generally
held that absorption of insulin from such palpably abnormal sites is ... Cited by 9 - Related articles - BL Direct - All 6 versions
D Owens, J Vora - Expert Opin. Drug Metab. Toxicol., 2006 - informahealthcare.com Insulin aspart, an analogue of human insulin, which is approved for use in
people with diabetes, is more rapidly absorbed and achieves higher plasma
concentrations than human soluble insulin following subcutaneous injection. ... Cited by 6 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org U Hiden, E Glitzner, M Ivanisevic, J Djelmis … - Diabetes, 2008 - Am Diabetes Assoc OBJECTIVE—In pregestational diabetes, the placenta at term of gestation is
characterized by various structural and functional changes. Whether similar
alterations occur in the first trimester has remained elusive. Placental ... Cited by 5 - Related articles - BL Direct - All 6 versions
A Agin, N Jeandidier, F Gasser, D Grucker, R … - Clinical Chemical Laboratory Medicine, 2006 - reference-global.com Background: In clinical studies involving rapid-acting analogues (RAAs), insulin
immunoreactivity is fre- quently measured, including endogenous, regular insulin
(RI) and RAA immunoreactivities. Such a pro- cedure implies equivalent ... Cited by 3 - Related articles - BL Direct - All 5 versions
SI Chisalita, T Lindström, PE: son Jennersjö … - Acta Diabetologica, 2009 - Springer Abstract Our aim was to study, at the same glycemic control, how treatment with
either the insulin secretagogue repaglinide or exogenous insulin aspart affects
endogenous insulin secretion, plasma insulin and IAPP (islet amyloid ... Cited by 1 - Related articles - All 3 versions
I Raz, R Weiss, Y Yegorchikov, G Bitton, R … - Clinical therapeutics, 2009 - Elsevier Methods: This was an open-label, randomized, 2-period, 1-way crossover study
using a meal tolerance test (MTT) protocol in subjects with type 1 diabetes
mellitus aged 18 to 65 years with glycosylated hemoglobin (HbA 1c ) of 6% ... Related articles - All 3 versions
Z Szabo, RGG Andersson, HJ Arnqvist - British Journal of Anaesthesia, 2009 - British Jrnl Anaesthesia Results: Glucose release from the diabetic muscle at the last sampling time was
detected. This was confirmed by a negative glucose A–I
(arterial–interstitial difference) in the muscle. No differences were ... Related articles - All 3 versions
